Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

标题
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
作者
关键词
Alirocumab, Ezetimibe, Low-density lipoprotein cholesterol, Monoclonal antibody, PCSK9, Rosuvastatin
出版物
ATHEROSCLEROSIS
Volume 244, Issue -, Pages 138-146
出版商
Elsevier BV
发表日期
2015-11-14
DOI
10.1016/j.atherosclerosis.2015.11.010

向作者/读者发起求助以获取更多资源

Reprint

联系作者

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now